VYNE

VYNE is a clinical-stage biopharma whose entire investment case has collapsed into a corporate transaction. Both lead assets are gone: repibresib (VYN201) missed its primary F-VASI50 endpoint in the Phase 2b vitiligo trial in July 2025 and was terminated, and VYN202 hit an April 2025 FDA clinical hold after testicular toxicity in dogs — only partially lifted, with the remedial male-dog toxicology study not finishing until 2H 2026. Management wound down both trials, went fully remote with no lease as of Dec 2025, and in December signed a merger agreement (amended Jan 2026) with Yarrow Biosciences — a reverse-merger structure where Yarrow survives inside VYNE. The company as it exists today is effectively a cash-and-listing vehicle, not an operating pipeline.

The numbers confirm this. Revenue is a rounding error ($570K FY2025) so the 39.7x P/S is meaningless. Losses are structural: -$26.5M net, -$29.7M operating, -4,646% net margin, -95.4% ROE, and -$758M accumulated deficit. The one genuine strength is the balance sheet — $24.0M cash, zero long-term debt, liabilities/equity of just 0.09x, and $27.8M equity — meaning the $22.7M market cap actually sits slightly below net cash. But that is not a value floor here: operating cash burn was -$33.1M in FY2025, so at the current run-rate the cash covers well under a year, and the share count already ballooned +119% to 33.3M, diluting existing holders.